Last reviewed · How we verify

Florbetapir F 18 (18F-AV-45)

University of California, San Francisco · FDA-approved active Small molecule

Florbetapir F 18 (18F-AV-45) is a PET imaging agent Small molecule drug developed by University of California, San Francisco. It is currently FDA-approved for Detection of amyloid-beta pathology in patients with cognitive impairment or suspected Alzheimer's disease. Also known as: Florbetapir, Amyvid 18F-AV-45.

Florbetapir F-18 is a positron emission tomography (PET) imaging agent that binds to amyloid-beta plaques in the brain to detect Alzheimer's disease pathology.

Florbetapir F-18 is a positron emission tomography (PET) imaging agent that binds to amyloid-beta plaques in the brain to detect Alzheimer's disease pathology. Used for Detection of amyloid-beta pathology in patients with cognitive impairment or suspected Alzheimer's disease.

At a glance

Generic nameFlorbetapir F 18 (18F-AV-45)
Also known asFlorbetapir, Amyvid 18F-AV-45
SponsorUniversity of California, San Francisco
Drug classPET imaging agent
TargetAmyloid-beta (Aβ) plaques
ModalitySmall molecule
Therapeutic areaNeurology / Alzheimer's disease
PhaseFDA-approved

Mechanism of action

Florbetapir F-18 is a fluorine-18 labeled tracer that crosses the blood-brain barrier and selectively binds to amyloid-beta aggregates, the hallmark pathological feature of Alzheimer's disease. When administered intravenously, it accumulates in brain regions with amyloid pathology and emits positrons that are detected by PET imaging, allowing visualization and quantification of amyloid burden. This enables early detection of amyloid pathology in patients with cognitive impairment or at risk for Alzheimer's disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Florbetapir F 18 (18F-AV-45)

What is Florbetapir F 18 (18F-AV-45)?

Florbetapir F 18 (18F-AV-45) is a PET imaging agent drug developed by University of California, San Francisco, indicated for Detection of amyloid-beta pathology in patients with cognitive impairment or suspected Alzheimer's disease.

How does Florbetapir F 18 (18F-AV-45) work?

Florbetapir F-18 is a positron emission tomography (PET) imaging agent that binds to amyloid-beta plaques in the brain to detect Alzheimer's disease pathology.

What is Florbetapir F 18 (18F-AV-45) used for?

Florbetapir F 18 (18F-AV-45) is indicated for Detection of amyloid-beta pathology in patients with cognitive impairment or suspected Alzheimer's disease.

Who makes Florbetapir F 18 (18F-AV-45)?

Florbetapir F 18 (18F-AV-45) is developed and marketed by University of California, San Francisco (see full University of California, San Francisco pipeline at /company/university-of-california-san-francisco).

Is Florbetapir F 18 (18F-AV-45) also known as anything else?

Florbetapir F 18 (18F-AV-45) is also known as Florbetapir, Amyvid 18F-AV-45.

What drug class is Florbetapir F 18 (18F-AV-45) in?

Florbetapir F 18 (18F-AV-45) belongs to the PET imaging agent class. See all PET imaging agent drugs at /class/pet-imaging-agent.

What development phase is Florbetapir F 18 (18F-AV-45) in?

Florbetapir F 18 (18F-AV-45) is FDA-approved (marketed).

What are the side effects of Florbetapir F 18 (18F-AV-45)?

Common side effects of Florbetapir F 18 (18F-AV-45) include Injection site reactions, Headache, Nausea.

What does Florbetapir F 18 (18F-AV-45) target?

Florbetapir F 18 (18F-AV-45) targets Amyloid-beta (Aβ) plaques and is a PET imaging agent.

Related